Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell save search
Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023
Published: 2023-07-26 (Crawled : 11:00) - globenewswire.com
MRKR | $4.4 -0.57% 5.42% 10K
|
Consumer Services
|
| O: 1.14%
H: 9.01%
C: -3.94%
cell car-t therapeutics
Crossbow Therapeutics Launches with $80 Million in Series A Financing to Advance a Novel Class of Antibody Therapies That Mimic T-Cell Receptors to Treat Cancer
Published: 2023-07-11 (Crawled : 13:00) - biospace.com/
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: -0.7%
H: 0.12%
C: -2.36%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
antibody t-cell cancer treat therapeutics
Global CAR-T Cell Therapy Market Report 2023: Rise in Awareness Regarding CAR T-Cell Therapy Drives Growth
Published: 2023-07-06 (Crawled : 19:00) - prnewswire.com
CRBU | $3.85 -3.27% -3.11% 230
|
Health Technology
|
| O: 0.32%
H: 25.69%
C: 21.83%
JNJ | News | $148.53 -0.69% 0.11% 67K
|
Health Technology
|
| O: -0.7%
H: 0.36%
C: -0.76%
AMGN | News | $273.01 -0.19% -0.17% 400
|
Health Technology
|
| O: -0.5%
H: 0.14%
C: -1.45%
report t-cell cell global car-t therapy growth market
A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US
Published: 2023-07-06 (Crawled : 11:00) - prnewswire.com
GDTC | $2.15 -2.04% 990
|
|
| O: 3.11%
H: 8.72%
C: 3.03%
patent granted cell technology therapeutics
CAR T-Cell Study Enabled by 10x Genomics Single Cell Technology Published in Nature Medicine
Published: 2023-07-06 (Crawled : 06:00) - biospace.com/
TXG | $27.52 -0.22% -0.2% 1.8M
|
Health Technology
|
| O: -2.0%
H: 1.42%
C: 0.28%
t-cell genomics cell technology study
CAR T-Cell Study Enabled by 10x Genomics Single Cell Technology Published in Nature Medicine
Published: 2023-07-05 (Crawled : 00:00) - prnewswire.com
TXG | $27.52 -0.22% -0.2% 1.8M
|
Health Technology
|
| O: -2.0%
H: 1.42%
C: 0.28%
t-cell genomics cell technology study
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-CD19CD20-ALLO1, an Allogeneic Dual CAR-T Cell Therapy for B-Cell Malignancies
Published: 2023-07-05 (Crawled : 13:00) - biospace.com/
PSTX | $2.07 -4.17% -4.6% 460K
|
Health Technology
|
| O: 8.67%
H: 13.2%
C: -9.57%
cd19 fda drug cell clearance application car-t therapeutics therapy
Global Chimeric Antigen Receptor T (CAR-T) Cells Market 2023: Industry Analysis Report Examines the $2.76 Billion Market
Published: 2023-06-29 (Crawled : 18:00) - prnewswire.com
NVSEF | News | $96.0 0.94% 6.88% 0
|
Health Technology
|
| O: 1.03%
H: 0.0%
C: -4.47%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: 0.74%
H: 0.81%
C: 0.81%
BMY | $48.86 -0.27% 0.98% 14M
|
Health Technology
|
| O: 0.44%
H: 0.2%
C: -0.51%
AUTL | $4.21 -6.03% -5.91% 12
|
Health Technology
|
| O: 1.75%
H: 3.97%
C: 2.59%
report global market
Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC
Published: 2023-06-29 (Crawled : 11:00) - globenewswire.com
GNLX | $3.45 -0.86% -0.87% 140K
|
|
| O: -0.03%
H: 3.07%
C: -1.54%
patent corporation cancer cell treatment
Viracta Therapeutics’ Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL)
Published: 2023-06-28 (Crawled : 12:00) - globenewswire.com
VIRX | $0.8363 -1.36% -1.33% 55K
|
Manufacturing
|
| O: 1.4%
H: 8.91%
C: 4.14%
t-cell expansion trial
Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan
Published: 2023-06-22 (Crawled : 13:00) - biospace.com/
GILD | $67.08 0.08% 0.06% 2.5K
|
Health Technology
|
| O: 0.18%
H: 0.57%
C: 0.46%
yescarta japan transfer t-cell authorization therapy
Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma
Published: 2023-06-16 (Crawled : 11:00) - globenewswire.com
AUTL | $4.21 -6.03% -5.91% 12
|
Health Technology
|
| O: 1.77%
H: 1.74%
C: 0.35%
t-cell positive therapeutics results
Panbela Announces Sponsored Research Agreement to Evaluate Polyamine Metabolic Inhibitor Therapy in Combination with CAR-T Cell Therapy
Published: 2023-06-13 (Crawled : 12:20) - globenewswire.com
PBLA | News | $0.4101 -2.36% -6.31% 14K
|
Professional, Scientific, and T...
|
| O: 13.23%
H: 22.83%
C: -16.44%
metabolic cell research car-t agreement therapy
Gracell Biotechnologies Presents Longer-Term Results for FasTCAR-T GC012F in B-Cell Non-Hodgkin’s Lymphoma at EHA2023, Highlighting 100% Overall Response Rate
Published: 2023-06-10 (Crawled : 16:20) - globenewswire.com
GRCL | $10.25 -0.29% 6.4M
|
Manufacturing
| Email alert
Add to watchlist
gc012 response results
Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of ROR1 targeting autologous CAR T, ONCT-808, in patients with relapsed or refractory aggressive B-cell lymphoma
Published: 2023-06-06 (Crawled : 20:00) - globenewswire.com
ONCT | $8.545 -2.51% -0.11% 1.6K
|
Health Technology
|
| O: -1.15%
H: 7.27%
C: 2.93%
onct-808 therapeutics study
Innovent and IASO Bio Updated Efficacy and Safety Clinical Data of Equecabtagene Autoleucel (BCMA CAR-T Cell Therapy) for Multiple Myeloma at the 2023 ASCO Annual Meeting
Published: 2023-06-06 (Crawled : 00:00) - prnewswire.com
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.94%
H: 0.27%
C: 0.02%
INCY | $51.74 0.17% 0.14% 2
|
Health Technology
|
| O: 0.45%
H: 0.14%
C: -1.5%
asco cell meeting car-t
Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients
Published: 2023-06-05 (Crawled : 20:00) - prnewswire.com
PGEN | $1.42 1.43% 1.41% 570K
|
Health Technology
|
| O: -0.75%
H: 2.26%
C: -2.26%
prgn-3005 day positive cancer
Kite’s Yescarta® CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
Published: 2023-06-05 (Crawled : 17:00) - biospace.com/
GILD | $67.08 0.08% 0.06% 2.5K
|
Health Technology
|
| O: -0.09%
H: 0.27%
C: -0.13%
yescarta t-cell treatment care therapy
CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics
Published: 2023-06-05 (Crawled : 13:00) - feed.businesswire.com
PBAX 4 | $5.85 -11.11% 6.5K
|
n/a
| Email alert
Add to watchlist
biotech cell acquisition therapeutics agreement
Coya Therapeutics Strengthens Scientific Advisory Board (SAB) with the Addition of Neuroimmunology Pioneer, Dr. Guillaume Dorothée, an Expert on the Role of the Immune System and Regulatory T Cells (Tregs) in Alzheimer’s Disease (AD)
Published: 2023-06-05 (Crawled : 12:00) - biospace.com/
COYA | News | $8.41 4.86% 3.14% 120K
|
|
| O: -2.19%
H: 5.59%
C: -6.04%
disease alzheimer’s system therapeutics
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K
|
n/a
MTH | $154.69 -2.21% 12.68% 450K
|
Consumer Durables
HCP | News | $31.41 7.75% 11.26% 1.2M
|
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
TAL | $12.26 0.57% 9.22% 12M
|
Consumer Services
ASXC | $0.243 -2.41% 7.0% 1.1M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.